{"slideshow_credits": null, "snippet": "The drug maker Actavis will acquire Forest Laboratories for about $25 billion. | King Digital Entertainment, the maker of Candy Crush Saga, has filed for an I.P.O. | Bitcoin is experiencing some growing pains. | Britain\u2019s Serious Fraud Office has...", "abstract": "The drug maker Actavis will acquire Forest Laboratories for about $25 billion. | King Digital Entertainment, the maker of Candy Crush Saga, has filed for an I.P.O. | Bitcoin is experiencing some growing pains. | Britain\u2019s Serious Fraud Office has begun criminal proceedings against three former Barclays employees suspected in the manipulation of Libor. | Comcast\u2019s proposed deal for Time Warner Cable could set off a frenzy of deal-making.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Sydney", "role": "reported", "lastname": "EMBER", "rank": 1, "organization": ""}], "original": "By SYDNEY EMBER"}, "web_url": "http://dealbook.nytimes.com/2014/02/18/morning-agenda-a-25-billion-deal-for-drug-makers/", "lead_paragraph": null, "headline": {"main": "A $25 Billion Deal for Drug Makers", "kicker": "DealBook"}, "_id": "5303563a38f0d821d3f24a81", "word_count": "2588", "multimedia": [], "pub_date": "2014-02-18T07:43:04Z", "source": "The New York Times", "news_desk": "Business", "keywords": [], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}